Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review

Canadian Journal of Gastroenterology and Hepatology

Volumn 29, Issue 3, 2015, Pages 157-163

  Alibrahim, Bashaar ^a,b   Aljasser, Mohammed I ^c   Salh, Baljinder ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Calprotectin; Fecal; Gastrointestinal disorders; Inflammatory bowel disease

Indexed keywords

CALGRANULIN; CALGRANULIN A; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; BIOLOGICAL MARKER;

ADENOMATOUS POLYP; AGE; ANKYLOSING SPONDYLITIS; CELIAC DISEASE; COLLAGENOUS COLITIS; COLORECTAL CANCER; CYSTIC FIBROSIS; DIVERTICULOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FECES LEVEL; FOOD ALLERGY; GASTROESOPHAGEAL REFLUX; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEITIS; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; LIVER CIRRHOSIS; MICROSCOPIC COLITIS; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; SYSTEMIC SCLEROSIS; TURNAROUND TIME; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MASS SCREENING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MASS SCREENING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84927155909     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2015/950286     Document Type: Review

References (73)

1. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-23.
2. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803-13.
3. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16(Suppl):273-82.
4. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-8.
5. Ton H, Brandsnes, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
6. Aadland E, Fagerhol MK. Faecal calprotectin: A marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823-5.
7. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:524-34.
8. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
9. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
10. Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: Systematic review and economic evaluation. Health Technol Assess 2013;17:xv-xix, 1-211.
11. Jellema P, van Tulder MW, van der Horst HE, et al. Inflammatory bowel disease: A systematic review on the value of diagnostic testing in primary care. Colorectal Dis 2011;13:239-54.
12. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010;341:c3369.
13. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
14. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19:332-41.
15. Lobaton T, Rodriguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034-42.
16. Faubion WA Jr, Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: Role of cross-sectional imaging. Am J Gastroenterol 2013;108:1891-900.
17. Mooiweer E, Fidder HH, Siersema PD, et al. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis 2014;20:307-14.
18. Schoepfer AM, Beglinger C, Straumann A, et al. Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-8.
19. Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-9.
20. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-9.
21. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-7.
22. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol 2014;12:253-62, e2.
23. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: An inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37.
24. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986;1:167-74.
25. Shepherd NA, Jass JR, Duval I, et al. Restorative proctocolectomy with ileal reservoir: Pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987;40:601-7.
26. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal calprotectin: A noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008;20:174-9.
27. Offner FA, Jao RV, Lewin KJ, et al. Collagenous colitis: A study of the distribution of morphological abnormalities and their histological detection. Hum Pathol 1999;30:451-7.
28. Wildt S, Nordgaard-Lassen I, Bendtsen F, et al. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007;19:567-74.
29. Larsson JK, Sjoberg K, Vigren L, et al. Chronic non-bloody diarrhoea: A prospective study in Malmo, Sweden, with focus on microscopic colitis. BMC Res Notes 2014;7:236.
30. Rodriguez-Otero P, Porcher R, Peffault de Latour R, et al. Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. Blood 2012;119:5909-17.
31. Chiusolo P, Metafuni E, Giammarco S, et al. Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. Blood 2012;120:4443-4.
32. Bastos Oreiro M, Castilla-Llorente C, de la Guia AL, et al. Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. Bone Marrow Transplant 2012;47:1241-2.
33. August KJ, Chiang KY, Qayed M, et al. Relative defects in mucosal immunity predict acute graft-versus-host disease. Biol Blood Marrow Transplant 2014;20:1056-9.
34. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:785-813, ix-x.
35. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23-31.
36. Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol 2010;37:2606-16.
37. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009;15:2449-55.
38. Rosenbaum J, Chandran V. Management of comorbidities in ankylosing spondylitis. Am J Med Sci 2012;343:364-6.
39. Matzkies FG, Targan SR, Berel D, et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: A pilot study. Arthritis Res Ther 2012;14:R261.
40. Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis-frequently elevated in feces, but normal in serum. Scand J Gastroenterol 2012;47:435-44.
41. Manetti M, Neumann E, Muller A, et al. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum 2008;58:2866-73.
42. Andreasson K, Scheja A, Saxne T, et al. Faecal calprotectin: A biomarker of gastrointestinal disease in systemic sclerosis. J Intern Med 2011;270:50-7.
43. Tursi A, Brandimarte G, Elisei W, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008;42:699-703.
44. Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in colonic diverticular disease: A case-control study. Int J Colorectal Dis 2009;24:49-55.
45. Montalto M, Santoro L, Curigliano V, et al. Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol 2007;42:957-61.
46. Capone P, Rispo A, Imperatore N, et al. Fecal calprotectin in coeliac disease. World J Gastroenterol 2014;20:611-2.
47. Balamtekin N, Baysoy G, Uslu N, et al. Fecal calprotectin concentration is increased in children with celiac disease: Relation with histopathological findings. Turk J Gastroenterol 2012;23:503-8.
48. Ertekin V, Selimoglu MA, Turgut A, et al. Fecal calprotectin concentration in celiac disease. J Clin Gastroenterol 2010;44:544-6.
49. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 1999;15:47-52.
50. Casellas F, Guarner L, Vaquero E, et al. Hydrogen breath test with glucose in exocrine pancreatic insufficiency. Pancreas 1998;16:481-6.
51. Madsen JL, Graff J, Philipsen EK, et al. Bile acid malabsorption or disturbed intestinal permeability in patients treated with enzyme substitution for exocrine pancreatic insufficiency is not caused by bacterial overgrowth. Pancreas 2003;26:130-3.
52. Pezzilli R, Barassi A, Morselli-Labate AM, et al. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: A possible link between pancreatic insufficiency and intestinal inflammation. J Gastroenterol 2007;42:754-60.
53. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008;121:1099-106.
54. Chen CC, Huang JL, Chang CJ, et al. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr 2012;55:541-7.
55. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71.
56. Gori A, Tincati C, Rizzardini G, et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008;46:757-8.
57. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
58. Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: Comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329-33.
59. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6.
60. Meling TR, Aabakken L, Roseth A, et al. Faecal calprotectin shedding after short-term treatment with non-steroidal antiinflammatory drugs. Scand J Gastroenterol 1996;31:339-44.
61. Poullis A, Foster R, Mendall MA, et al. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003;15:573-4.
62. Khalid U, McGough C, Hackett C, et al. A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading. Int J Radiat Oncol Biol Phys 2006;64:1432-41.
63. Wedlake L, McGough C, Hackett C, et al. Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa? Aliment Pharmacol Ther 2008;27:980-7.
64. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353-72.
65. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010;53:849-55.
66. Gundling F, Schmidtler F, Hapfelmeier A, et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int 2011;31:1406-15.
67. Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004;36:467-70.
68. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin Chem 2003;49:861-7.
69. Smyth RL, Croft NM, O'Hea U, et al. Intestinal inflammation in cystic fibrosis. Arch Dis Child 2000;82:394-9.
70. Raia V, Maiuri L, de Ritis G, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res 2000;47:344-50.
71. Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004;20:813-9.
72. Mercer DF, Vargas L, Sun Y, et al. Stool calprotectin monitoring after small intestine transplantation. Transplantation 2011;91:1166-71.
73. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002;34:323-4.